Vyalev is a follow up to AbbVie's 2015-approved Parkinson's infusion pump Duopa. (AbbVie) AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of ...
Vyalev combines foscarbidopa, a prodrug of carbidopa, and foslevodopa, a prodrug of levodopa, into a solution for continuous subcutaneous 24-hour infusion. The Food and Drug Administration (FDA) has ...
New continuous medication therapy helps provide more consistent symptom control for patients with advanced Parkinson’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results